Insulet Corp.’s PODD groundbreaking Omnipod 5 Automated Insulin Delivery (“AID”) system (Omnipod 5) received the FDA’s approval for use by type 2 diabetes patients (ages 18 years and above).

In December, a Massachusetts corporation won the largest jury verdict ever awarded under the federal Defend Trade Secrets Act ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...

When [Pete Schwamb]’s daughter received one of these pumps, an Omnipod, he responded to a bounty offer for reverse engineering its RF protocol. As one of the people who helped create Loop ...

Question: How is the Omnipod system covered under Medicare now that my doctor and I are considering it to help control my diabetes? Answer: The Omnipod system is an insulin delivery system that allows ...

Valued at a market cap of $18.5 billion, Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery ...

One challenger to Medtronic is Insulet. It already markets its Omnipod, the world's first tubeless insulin management system, but has now released data for its own hybrid closed loop system.

Insulet, a tubeless insulin pump technology company, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System in Germany, for people aged two-years and older with type ...

CER growth exceeded the company’s guidance of 21%. Insulet’s total Omnipod revenues of $533.6 million reflected an increase of 26.4% year over year (up 26.1% at CER). International Omnipod ...

BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...